Legend Biotech reports 100% response rate, favorable safety in Phase 1 LB2501 CAR-T trial
Legend Biotech reports 100% response rate, favorable safety in Phase 1 LB2501 CAR-T trial for B-cell lymphoma
- Initial Phase 1 data showed a 100% objective response rate in relapsed/refractory B-cell non-Hodgkin lymphoma.
- LB2501 is an in vivo CD19/CD20 CAR-T candidate being evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma.
- The LB2501 data will be presented in a late-breaking oral session at EHA 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.